BRIEF-Puma Biotechnology And Pierre Fabre Amend Nerlynx License Agreement
BRIEF-Puma Biotechnology And Pierre Fabre Amend Nerlynx License Agreement
Feb 25 (Reuters) - Puma Biotechnology Inc :
* PUMA BIOTECHNOLOGY AND PIERRE FABRE AMEND NERLYNX® LICENSE AGREEMENT TO INCLUDE GREATER CHINA
* PUMA BIOTECHNOLOGY INC - CO, CANBRIDGE PHARMACEUTICALS TERMINATE LICENSE AGREEMENT IN GREATER CHINA
* PUMA BIOTECHNOLOGY INC - UNDER TERMS, CO WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION
* PUMA BIOTECHNOLOGY - UNDER TERMS, CO WILL RECEIVE AN ADDITIONAL REGULATORY, SALES-BASED MILESTONE PAYMENTS THAT COULD ADD UP TO AN ADDITIONAL $240 MILLION
* PUMA BIOTECHNOLOGY INC - IN ADDITION, PUMA WILL RECEIVE SIGNIFICANT DOUBLE-DIGIT TIERED ROYALTIES ON SALES OF NERLYNX IN GREATER CHINA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透2月25日电-彪马生物技术公司(Puma Biotechnology Inc):*PUMA生物技术和Pierre Fabre修改NERLYNX®许可协议,将大中华区包括在内*PUMA生物技术公司-CO,Canbridge制药公司在大中华区终止许可协议*PUMA生物技术公司-根据条款,CO将收到5000万美元的预付款*PUMA生物技术-根据条款,CO将获得额外的监管、基于销售的里程碑付款,总计可能额外获得2.4亿美元*PUMA生物技术公司-此外,PUMA将从NERLYNX在大中华区的销售中获得可观的两位数分级特许权使用费Eikon的源文本:进一步的公司报道:(Reurs.Briefs@thomsonreurs.com;)
译文内容由第三方软件翻译。